IX BIOPHARMA LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.042 SGD | +2.44% |
|
+5.00% | -6.67% |
| Mar. 12 | Singaporean Shares End Marginally Higher; Biopharma's Shares Climb 2% on Introduction of New Sublingual Wafer | MT |
| Mar. 12 | IX Biopharma Introduces New Sublingual Wafer | MT |
Valuation
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 110.5 | 164.4 | 162.2 | 167.4 | 122.4 | 69.73 |
| Enterprise Value (EV) 1 | 93.87 | 152.3 | 160.4 | 165.4 | 113.3 | 67.54 |
| P/E ratio | -7.17 x | -54.6 x | -15.4 x | -20 x | -26.3 x | -7.22 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 16.9 x | 245 x | 165 x | 95.9 x | 8.51 x | 11.8 x |
| EV / Revenue | 14.4 x | 227 x | 163 x | 94.8 x | 7.87 x | 11.4 x |
| EV / EBITDA | -6.7 x | -13.9 x | -14.5 x | -15.3 x | 98.6 x | -7.47 x |
| EV / FCF | -16.7 x | -13 x | -26.2 x | -25.6 x | 30.1 x | -10.3 x |
| FCF Yield | -5.98% | -7.7% | -3.82% | -3.91% | 3.32% | -9.74% |
| Price to Book | 5.14 x | 8.02 x | 16 x | 14.3 x | 6.2 x | 4.4 x |
| Nbr of stocks (in thousands) | 642,696 | 644,594 | 648,894 | 697,353 | 751,190 | 766,300 |
| Reference price 2 | 0.1720 | 0.2550 | 0.2500 | 0.2400 | 0.1630 | 0.0910 |
| Announcement Date | 9/26/18 | 9/25/19 | 9/30/20 | 9/28/21 | 9/22/22 | 9/25/23 |
1SGD in Million2SGD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 6.533 | 0.671 | 0.985 | 1.745 | 14.39 | 5.913 |
| EBITDA 1 | -14 | -10.98 | -11.04 | -10.81 | 1.149 | -9.043 |
| EBIT 1 | -15.33 | -12.14 | -11.69 | -11.43 | 0.501 | -9.544 |
| Operating Margin | -234.61% | -1,809.09% | -1,186.9% | -654.96% | 3.48% | -161.41% |
| Earnings before Tax (EBT) 1 | -15.16 | -13.27 | -10.5 | -8.233 | -4.099 | -9.706 |
| Net income 1 | -15.09 | -2.991 | -10.5 | -8.234 | -4.598 | -9.615 |
| Net margin | -231.04% | -445.75% | -1,065.89% | -471.86% | -31.95% | -162.61% |
| EPS 2 | -0.0240 | -0.004671 | -0.0162 | -0.0120 | -0.006200 | -0.0126 |
| Free Cash Flow 1 | -5.618 | -11.73 | -6.13 | -6.465 | 3.764 | -6.575 |
| FCF margin | -86% | -1,747.82% | -622.3% | -370.48% | 26.16% | -111.2% |
| FCF Conversion (EBITDA) | - | - | - | - | 327.58% | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 9/26/18 | 9/25/19 | 9/30/20 | 9/28/21 | 9/22/22 | 9/25/23 |
1SGD in Million2SGD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 16.7 | 12.1 | 1.83 | 1.98 | 9.18 | 2.2 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -5.62 | -11.7 | -6.13 | -6.46 | 3.76 | -6.58 |
| ROE (net income / shareholders' equity) | -52.8% | -63% | -68.5% | -75.3% | -29.2% | -54% |
| ROA (Net income/ Total Assets) | -24.8% | -25.4% | -33.5% | -39.9% | 1.32% | -22.3% |
| Assets 1 | 60.92 | 11.78 | 31.37 | 20.66 | -347.8 | 43.07 |
| Book Value Per Share 2 | 0.0300 | 0.0300 | 0.0200 | 0.0200 | 0.0300 | 0.0200 |
| Cash Flow per Share 2 | 0.0300 | 0.0200 | 0.0100 | 0.0100 | 0.0200 | 0.0100 |
| Capex 1 | 1.12 | 1.53 | 0.98 | 0.55 | 0.2 | 0.7 |
| Capex / Sales | 17.11% | 228.61% | 99.9% | 31.69% | 1.39% | 11.75% |
| Announcement Date | 9/26/18 | 9/25/19 | 9/30/20 | 9/28/21 | 9/22/22 | 9/25/23 |
1SGD in Million2SGD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -6.67% | 23.68M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 42C Stock
- Financials iX Biopharma Ltd.
